EA201590554A1 - Ингибиторы глюкозилцерамид-синтазы - Google Patents

Ингибиторы глюкозилцерамид-синтазы

Info

Publication number
EA201590554A1
EA201590554A1 EA201590554A EA201590554A EA201590554A1 EA 201590554 A1 EA201590554 A1 EA 201590554A1 EA 201590554 A EA201590554 A EA 201590554A EA 201590554 A EA201590554 A EA 201590554A EA 201590554 A1 EA201590554 A1 EA 201590554A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glukosilzeramid
treatment
synthase inhibitors
applicable
inhibitors
Prior art date
Application number
EA201590554A
Other languages
English (en)
Other versions
EA038536B1 (ru
Inventor
Элиз Бурке
Марио А. Кабрера-Салазар
Кассандра Селатка
Сэн Х. Чэн
Брэдфорд Херт
Эндрю Гуд
Кэтрин Джэнксикс
Джон Маршалл
Маркус Метц
Рональд К. Шойле
Ренато Скерлдж
Ибинь Сян
Чжун Чжао
Джон Леонард
Томас Натоли
Элина Макино
Эрве Хассон
Оксана Бескровная
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201590554A1 publication Critical patent/EA201590554A1/ru
Publication of EA038536B1 publication Critical patent/EA038536B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Изобретение относится к ингибиторам глюкозилцерамид-синтазы (GCS), применимым для лечения болезней обмена веществ, таких как лизосомные болезни накопления, применимым или одних, или в комбинации с ферментной заместительной терапией для лечения кистозной болезни или для лечения рака.
EA201590554A 2012-09-11 2013-09-10 Ингибиторы глюкозилцерамид-синтазы EA038536B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699714P 2012-09-11 2012-09-11
PCT/US2013/058896 WO2014043068A1 (en) 2012-09-11 2013-09-10 Glucosylceramide synthase inhibitors

Publications (2)

Publication Number Publication Date
EA201590554A1 true EA201590554A1 (ru) 2015-07-30
EA038536B1 EA038536B1 (ru) 2021-09-10

Family

ID=49226563

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091568A EA202091568A1 (ru) 2012-09-11 2013-09-10 Ингибиторы глюкозилцерамид-синтазы
EA201590554A EA038536B1 (ru) 2012-09-11 2013-09-10 Ингибиторы глюкозилцерамид-синтазы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202091568A EA202091568A1 (ru) 2012-09-11 2013-09-10 Ингибиторы глюкозилцерамид-синтазы

Country Status (38)

Country Link
US (3) US20150210681A1 (ru)
EP (2) EP4098654A1 (ru)
JP (1) JP6430943B2 (ru)
KR (1) KR102216532B1 (ru)
CN (3) CN108864076B (ru)
AR (1) AR092522A1 (ru)
AU (1) AU2013315715A1 (ru)
BR (1) BR112015005227A2 (ru)
CA (1) CA2884144C (ru)
CL (1) CL2015000529A1 (ru)
CR (1) CR20150150A (ru)
DK (1) DK2895484T3 (ru)
DO (1) DOP2015000039A (ru)
EA (2) EA202091568A1 (ru)
ES (1) ES2911685T3 (ru)
GT (1) GT201500051A (ru)
HK (1) HK1212681A1 (ru)
HR (1) HRP20220310T1 (ru)
HU (1) HUE058085T2 (ru)
IL (1) IL237355B (ru)
JO (1) JOP20130273B1 (ru)
LT (1) LT2895484T (ru)
MA (1) MA37975B2 (ru)
MX (2) MX2015003043A (ru)
MY (1) MY186824A (ru)
NZ (1) NZ706296A (ru)
PE (1) PE20150734A1 (ru)
PH (1) PH12015500431B1 (ru)
PL (1) PL2895484T3 (ru)
PT (1) PT2895484T (ru)
RS (1) RS63130B1 (ru)
SG (2) SG10201701966RA (ru)
SI (1) SI2895484T1 (ru)
TN (1) TN2015000091A1 (ru)
TW (1) TWI627171B (ru)
UA (1) UA118747C2 (ru)
UY (1) UY35024A (ru)
WO (1) WO2014043068A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014151291A1 (en) 2013-03-15 2014-09-25 Genzyme Corporation Method of preparing glucosylceramide synthase inhibitors
EP3079695B1 (en) * 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
BR112017002003A2 (pt) * 2014-08-04 2017-12-12 Genzyme Corp biomarcadores de doença renal policística e usos dos mesmos
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
JP6895963B2 (ja) * 2015-11-18 2021-06-30 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
EP3464272B1 (en) 2016-06-07 2021-12-08 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
EP3728265A1 (en) 2017-12-21 2020-10-28 BIAL - BioTech Investments, Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
CN109709202A (zh) * 2018-12-29 2019-05-03 辉源生物科技（上海）有限公司 一种半乳糖神经酰胺转移酶抑制剂药物的快速筛选方法
EP3920912A1 (en) * 2019-02-04 2021-12-15 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
JP2022521825A (ja) * 2019-03-28 2022-04-12 エッサ ファーマ，インコーポレイテッド アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
MX2021015503A (es) 2019-06-14 2022-04-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
WO2020249792A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
WO2021020362A1 (ja) 2019-07-29 2021-02-04 武田薬品工業株式会社 複素環化合物
JPWO2021020363A1 (ru) 2019-07-29 2021-02-04
KR102483495B1 (ko) * 2019-09-02 2023-01-04 한양대학교 에리카산학협력단 2,4-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물
US20230002380A1 (en) * 2019-11-15 2023-01-05 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
CA3154313A1 (en) * 2019-11-15 2021-05-20 Dong-Hoon Kim Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
JP2023512366A (ja) * 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
JP2023522040A (ja) 2020-04-17 2023-05-26 エッサ ファーマ，インコーポレイテッド Ｎ末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물
BR112023022015A2 (pt) * 2021-05-11 2023-12-26 Green Cross Corp Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas
WO2023101895A1 (en) * 2021-11-30 2023-06-08 Merck Sharp & Dohme Llc Fused pyrazole urea analogs as glucosylceramide synthase inhibitors
WO2023172475A2 (en) * 2022-03-11 2023-09-14 Merck Sharp & Dohme Llc Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors
WO2023177563A2 (en) * 2022-03-14 2023-09-21 Merck Sharp & Dohme Llc Fused pyrazole amide analogs as glucosylceramide synthase inhibitors

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (ru) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4593034A (en) * 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
ATE85217T1 (de) * 1988-08-04 1993-02-15 Synthelabo Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide.
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
IT1228293B (it) 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9106571D0 (en) 1991-03-27 1991-05-15 Erba Carlo Spa Derivatives of substituted imidazol-2-one and process for their preparation
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2182568A1 (en) * 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
AU7551896A (en) 1995-11-08 1997-05-29 American Home Products Corporation 1-azabicycloheptane derivatives and their pharmaceutical use
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EP0923536A1 (en) 1996-07-29 1999-06-23 Pharmacia & Upjohn Aktiebolag Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
EP2147681A1 (en) 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
EP1125922A1 (en) 1998-11-02 2001-08-22 Welfide Corporation Pyrrolidine compounds and medicinal utilization thereof
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
PL357099A1 (en) * 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AU6610001A (en) * 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
US6492386B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) * 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
JP2003267977A (ja) 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
US7985760B2 (en) 2002-07-17 2011-07-26 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
AU2003248122A1 (en) 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
JP4750421B2 (ja) * 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
AU2005258274A1 (en) 2004-06-23 2006-01-05 The Feinstein For Medical Research Method of treating ileus by pharmacological activation of cholinergic receptors
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
KR20080048550A (ko) * 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
CN101379065A (zh) * 2006-01-23 2009-03-04 克里斯特尔吉诺密斯株式会社 抑制蛋白质激酶活性的咪唑并吡啶衍生物、其制备方法和包含它的药物组合物
US20090170847A1 (en) * 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
US20090318491A1 (en) * 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
CN101605784B (zh) * 2007-02-09 2013-04-10 安斯泰来制药株式会社 氮杂桥环化合物
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
GB2466912B (en) 2007-11-29 2012-01-04 Hospital For Sick Children Compositions and methods for treating lysosomal disorders
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
CN102438988B (zh) * 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SI3482767T1 (sl) 2009-08-28 2022-03-31 Icahn School Of Medicine At Mount Sinai Encimska nadomestna terapija s povečevanjem odmerkov za zdravljenje pomanjkanja kisle sfingomielinaze
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
WO2012129084A2 (en) * 2011-03-18 2012-09-27 Genzyme Corporation Glucosylceramide synthase inhibitors
NZ742241A (en) 2012-09-11 2019-08-30 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
CN105073745B (zh) 2018-06-29
PH12015500431A1 (en) 2015-04-20
CA2884144A1 (en) 2014-03-20
EA202091568A1 (ru) 2020-12-30
PE20150734A1 (es) 2015-06-02
AR092522A1 (es) 2015-04-22
ES2911685T3 (es) 2022-05-20
MX2015003043A (es) 2015-11-09
EP2895484B1 (en) 2022-02-23
UY35024A (es) 2014-04-30
CA2884144C (en) 2023-10-17
PT2895484T (pt) 2022-05-06
CL2015000529A1 (es) 2015-11-13
US20220073508A1 (en) 2022-03-10
KR20150053972A (ko) 2015-05-19
EP2895484A1 (en) 2015-07-22
US20180065957A1 (en) 2018-03-08
LT2895484T (lt) 2022-03-25
RS63130B1 (sr) 2022-05-31
JP6430943B2 (ja) 2018-11-28
HK1212681A1 (zh) 2016-06-17
CN108864076B (zh) 2022-02-11
JP2015527406A (ja) 2015-09-17
US11008316B2 (en) 2021-05-18
TN2015000091A1 (en) 2016-06-29
CN114533729A (zh) 2022-05-27
DOP2015000039A (es) 2015-04-15
TW201422614A (zh) 2014-06-16
MA37975A1 (fr) 2016-09-30
SG10201701966RA (en) 2017-04-27
JOP20130273B1 (ar) 2021-08-17
MY186824A (en) 2021-08-23
IL237355A0 (en) 2015-04-30
HRP20220310T1 (hr) 2022-05-13
IL237355B (en) 2019-07-31
BR112015005227A2 (pt) 2017-07-04
NZ706296A (en) 2018-07-27
SI2895484T1 (sl) 2022-04-29
SG11201501538VA (en) 2015-03-30
GT201500051A (es) 2017-12-15
UA118747C2 (uk) 2019-03-11
PL2895484T3 (pl) 2022-10-03
EP4098654A1 (en) 2022-12-07
PH12015500431B1 (en) 2015-04-20
AU2013315715A1 (en) 2015-04-09
MA37975B2 (fr) 2021-03-31
KR102216532B1 (ko) 2021-02-16
HUE058085T2 (hu) 2022-06-28
WO2014043068A1 (en) 2014-03-20
CN105073745A (zh) 2015-11-18
US20150210681A1 (en) 2015-07-30
TWI627171B (zh) 2018-06-21
CR20150150A (es) 2015-06-11
CN108864076A (zh) 2018-11-23
DK2895484T3 (da) 2022-05-09
EA038536B1 (ru) 2021-09-10
MX2020002867A (es) 2021-10-26

Similar Documents

Publication Publication Date Title
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
SG10201804952QA (en) Glucosylceramide synthase inhibitors
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
TH153719A (th) สารยับยั้งของกลูโคซิลเซรามีดซินเทส
UA112059C2 (uk) Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти)
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM